Health Catalyst (NASDAQ:HCAT) Exceeds Q2 CY2026 Expectations But Stock Drops 25.5%
Health Catalyst (NASDAQ:HCAT) reported Q2 CY2026 revenue of $70.49 million, down 12.7% year on year, but above analysts’ estimates by 2.1%. Non-GAAP EPS was $0.04, in line with consensus. Next-quarter revenue guidance was $55.5 million, 10.7% below estimates. The stock fell 25.5% to $1.71 after results.
How this was made
The 30-second read
Why it matters
Traders should focus on the forward revenue guidance miss and the company’s cash-related billings trend and customer acquisition efficiency, which can affect liquidity and demand expectations.
Market read
Despite a Q2 revenue beat, the weaker next-quarter revenue guidance and negative cash/efficiency signals align with the reported 25.5% stock drop.
What to watch
The article highlights billings and CAC payback deterioration, but it does not quantify contract duration, churn, or backlog quality, which could change the interpretation of the revenue guide.
Background
Health Catalyst is a healthcare data analytics provider using its “Health Catalyst Flywheel” approach, and this article frames its Q2 CY2026 results versus expectations.
Ticker impact
Health Catalyst beat Q2 revenue expectations but guided next-quarter revenue to $55.5M, 10.7% below estimates, and shares fell 25.5%.
Bearish near-term bias, with follow-through risk if investors focus on the revenue guide and billings/CAC deterioration rather than the Q2 beat.
The article provides concrete datapoints: Q2 revenue $70.49M (beat by 2.1%), next-quarter revenue guidance $55.5M (10.7% below estimates), and a 25.5% immediate stock drop, plus billings and CAC payback deterioration that can reinforce liquidity and demand concerns.
Market effects
Reinforces that healthcare analytics/software names can trade on forward revenue guidance and cash-related metrics, not just quarterly beats.
Limited, single-name earnings reaction with no broader macro/regional catalyst cited.
Low, no international deal/regulatory developments mentioned.
Counterpoint
The company exceeded the high end of revenue guidance and matched non-GAAP EPS, so the selloff may over-discount a single-quarter guide if execution improves in subsequent quarters.
Key entities
- companyHealth Catalyst
NASDAQ-listed healthcare data analytics company reporting Q2 CY2026 results and next-quarter revenue guidance.
- executiveBen Albert
CEO quoted saying the company exceeded the high end of revenue guidance and the midpoint of adjusted EBITDA guidance.
